At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PALI Palisade Bio Inc.
Pre-Market Trading 12-23 06:10:32 EST
1.75
-0.05
-2.78%
盘前1.81
+0.06+3.43%
06:04 EST
High1.86
Low1.75
Vol124.37K
Open1.79
D1 Closing1.80
Amplitude6.11%
Mkt Cap2.93M
Tradable Cap2.81M
Total Shares1.67M
T/O222.34K
T/O Rate7.75%
Tradable Shares1.61M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Palisade Bio appoints Feagan to Clinical Advisory Board
Palisade Bio Announces Preliminary Data From Phase 1 Clinical Study of Pali-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to Be Safe and Well Tolerated in Treated Subjects
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.